EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study

Simona Catozzi, Souad Assaad, Lidia Delrieu, Bertrand Favier, Elise Dumas, Anne-Sophie Hamy, Aurélien Latouche, Hugo Crochet, Jean-Yves Blay, Jimmy Mullaert, Annabelle Ballesta, Pierre Heudel

European Journal of Cancer · 2024-03 · 199 · 113571

DOI: 10.1016/j.ejca.2024.113571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2024-03. Verfasst von Simona Catozzi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Inserm U900, Cancer Systems Pharmacology, Institut Curie, MINES ParisTech, CBIO, PSL Research University, 35 rue Dailly, 92250 Saint-Cloud, France. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Second Primary. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasms, Second PrimaryMaleHumansFemaleMiddle AgedImmune Checkpoint InhibitorsRetrospective StudiesDrug ChronotherapyProspective Studies

Stichwörter der Autor:innen

Administration time-of-dayChronotherapyCircadian drug timingImmune checkpoint blockadePrecision medicine

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Inserm U900, Cancer Systems Pharmacology, Institut Curie, MINES ParisTech, CBIO, PSL Research University, 35 rue Dailly, 92250 Saint-Cloud, France.
  • Département de cancérologie médicale, Centre Léon Bérard, 28 rue Laennec, 69008 Lyon, France.
  • Residual Tumour and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, Paris University, 75005 Paris, France.
  • Département de pharmacie oncologique, Centre Léon Bérard, 28 rue Laennec, 69008 Lyon, France.
  • Residual Tumour and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, Paris University, 75005 Paris, France; Medical oncology, Université Pari…
  • INSERM U900, Statistical Methods for Precision Medicine Institut Curie, PSL Research University, 35 rue Dailly, Saint-Cloud, France; Conservatoire National des Arts et Métiers, Paris, France.

Zitieren

APA

Catozzi, S., Assaad, S., Delrieu, L., Favier, B., Dumas, E., Hamy, A. S., Latouche, A., Crochet, H., Blay, J. Y., Mullaert, J., Ballesta, A., & Heudel, P. (2024). Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study. European Journal of Cancer, 199, 113571. https://doi.org/10.1016/j.ejca.2024.113571

Vancouver

Catozzi S, Assaad S, Delrieu L, Favier B, Dumas E, Hamy AS, et al. Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study. European Journal of Cancer. 2024;199:113571. doi:10.1016/j.ejca.2024.113571

BibTeX
@article{Catozzi2024,
  author = {Catozzi, Simona and Assaad, Souad and Delrieu, Lidia and Favier, Bertrand and Dumas, Elise and Hamy, Anne-Sophie and Latouche, Aurélien and Crochet, Hugo and Blay, Jean-Yves and Mullaert, Jimmy and Ballesta, Annabelle and Heudel, Pierre},
  title = {Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {199},
  pages = {113571},
  doi = {10.1016/j.ejca.2024.113571}
}
Kostenlos starten →